Primary Biliary Cholangitis clinical trials at UCSF
1 research study open to eligible people
Primary biliary cholangitis is a liver disease that affects bile ducts. UCSF is researching how Seladelpar affects people with this disease and compensated cirrhosis. The study aims to evaluate the drug's impact on health outcomes for these patients.
Showing trials for
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
open to eligible people ages 18 years and up
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
San Francisco, California and other locations
Last updated: